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Abstract
Background: Cadmium poisoning in the environment has assumed an alarming problem in recent
years. Effective antimutagenic agents which can reverse or combat cadmium induced genotoxicity
in mice have not yet been reported. Therefore, in the present study, following the homeopathic
principle of "like cures like", we tested the efficacy of two potencies of a homeopathic drug,
Cadmium Sulphoricum (Cad Sulph), in reducing the genotoxic effects of Cadmium chloride in mice.
Another objective was to determine the relative efficacy of three administrative modes, i.e. pre-,
post- and combined pre and post-feeding of the homeopathic drugs. For this, healthy mice, Mus
musculus, were intraperitoneally injected with 0.008% solution of CdCl2 @ 1 ml/100 gm of body
wt (i.e. 0.8 mcg/gm of bw), and assessed for the genotoxic effects through such studies as
chromosome aberrations (CA), micronucleated erythrocytes (MNE), mitotic index (MI) and sperm
head anomaly (SHA), keeping suitable succussed alcohol fed (positive) and CdCl2 untreated normal
(negative) controls. The CdCl2 treated mice were divided into 3 subgroups, which were orally
administered with the drug prior to, after and both prior to and after injection of CdCl2 at specific
fixation intervals and their genotoxic effects were analyzed.
Results: While the CA, MNE and SHA were reduced in the drug fed series as compared to their
respective controls, the MI showed an apparent increase. The combined pre- and post-feeding of
Cad Sulph showed maximum reduction of the genotoxic effects.
Conclusions: Both Cad Sulph-30 and 200 were able to combat cadmium induced genotoxic
effects in mice and that combined pre- and post-feeding mode of administration was found to be
most effective in reducing the genotoxic effect of CdCl2 followed by the post-feeding mode.
Background
Cadmium has been known as a toxic agent in environ-
ment which has attracted critical attention for its toxic
biological effects [1–10]. The adverse effects of cadmium
in biological systems may result in nephrotoxicity, tum-
origenicity or carcinogenicity in fowl, mice, rat and hu-
man beings [11–22]. Mutagenic effects of cadmium have
been extensively studied in microorganisms [23–25] and
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in mammals in vivo[22,26,27]. However, although cad-
mium poisoning has become an environmental hazard in
recent years, attempts to reduce cadmium induced geno-
toxicity by any possible antimutagenic agent(s) are very
few [28,29].
In the present study two microdoses of a potentized ho-
meopathic drug Cadmium Sulphoricum (Cad Sulph) –
30 and 200 were fed to mice either before or after the in-
jection of 0.008% CdCl2 @ 1 ml/100 gm of body weight
of mouse, to examine if either or both of these potencies
could positively modulate the cytogenetic effects pro-
duced by CdCl2. In fact, the impetus of the study was
drawn from our findings that potentized homeopathic
drug Arsenicum Album (Ars Alb), derived from succus-
sion and dilution of Arsenic trioxide could successfully
and favourably modulate cytotoxic and genotoxic effects
of Arsenic trioxide [30–35]. A little deviation has been
made in the present experimentation; the homeopathic
drug used has actually been derived from a different salt
of cadmium through dilution and succussion as per the
homeopathic procedure and it was examined if this drug
had any ameliorating effect on the genotoxicity produced
by the injection of CdCl2, another cadmium salt. Unfor-
tunately, as homeopathic preparations of Cad Chlor-30/
200 were not available, it was not possible to compare
the effects of Cad Chlor and Cad Sulph in combating cad-
mium poisoning. Another objective of the study was to
test the comparative efficacies of the three modes of
treatment, i.e., pre-, post- and combined pre- and post-
feeding of the homeopathic drug in combating sub-acute
cadmium poisoning.
Materials and Methods
Materials
Inbred lines of mice (Mus musculus) cultured and main-
tained on artificial standard diet and water ad libitum
(under the supervision of the animal welfare committee,
University of Kalyani) were used as materials for the
present study. Generally 3–4 months old healthy adult
mice of both sexes weighing between 22–28 gms were
selected for the purpose.
Methods
Treatment of test chemical
Mice were intraperitoneally injected with a single dose of
aqueous solution of CdCl2 (0.008%) at the rate of 1 ml/
100 gms of body weight (i.e. 0.8 mcg/g of bw approx) and
were sacrificed at 6 different fixation intervals, viz. at 6
hr, 12 hr, 24 hr, 48 hr, 72 hr and 96 hr.
Administration of potentized homeopathic drug
0.06 ml of each of the 30th and 200th potency of the ho-
meopathic drug Cadmium sulphoricum in liquid (90%
ethyl alcohol) prepared by the standard homeopathic
procedure of centesimal dilutions and succussions
[32,33] by Hapco, 165 Bipin Behari Ganguly Street, Kolk-
ata, was diluted separately with 20 ml of double distilled
water to make stock solutions of the homeopathic drug
that was orally administered to experimental mice. In In-
dia, these two potencies are most commonly used by the
homeopathic practitioners and are easily available in the
market.
Experimental design and control
Drug treated series
Drug pre-treated series (T1–T2)
1 drop of stock solution (0.06 ml) of the homeopathic
drug (both 30th and 200th potencies in separate series)
was orally administered to mice with the aid of a pipette
every 4 hr prior to the injection of CdCl2. The respective
times of beginning of drug feeding before injection were
6 hr, 12 hr, 24 hr, 48 hr, 72 hr and 96 hr to the sets of
mice destined to be sacrificed at 6 hr, 12 hr, 24 hr, 48 hr,
72 hr and 96 hr, respectively. As for example, the mice
destined to be sacrificed at 24 hr would start receiving
Photomicrograph 1
Photomicrographs. 1a-1j: Photomicrographs different types
of chromosome aberrations showing gap (1a), break (1b),
fragment of unknown origin (1c), terminal association (1d),
ring and constriction (1e), precocious centromeric separa-
tion (1f), C-mitotic effect (1g), pulverisation (1h), erosion (1i)
and polyploidy (1j). 1k-1l: Showing micronucleus in both
polychromatic (1k) and normochromatic (1l) erythrocytes.
1m-1o: Showing sperm with abnormal head-shapes (1m to
1o).BMC Complementary and Alternative Medicine 2001, 1:9 http://www.biomedcentral.com/1472-6882/1/9
the homeopathic drug 24 hr before Cadmium chloride
injection and those destined to be sacrificed at 48 hr
would start receiving the drug 48 hr before injection. In
case of pre-fed series, the mice were not fed homeopathic
drug after injection. But in the pre- and post-fed com-
bined series, the mice were fed the homeopathic drug
both prior to and after the injection. Similarly, in the
post-fed series, mice were fed the homeopathic drug only
after injection of Cadmium chloride.
Drug post-treated series (T3–T4)
Different sets (consisting of 5 mice each) of adult healthy
mice were fed 1 drop (0.06 ml) of the stock solution of
drug (either 30th or 200th potency) at an interval of 4
hour (during day time only i.e. generally 4 times a day)
i.e. the drug was fed twice at an interval of 4 hour to mice
sacrificed at 6 hr, thrice to mice sacrificed at 12 hr and 6
times to mice sacrificed at 24 hr and so on, starting at 5
minutes after injection.
Combined pre- and post-drug treated series (T5–T6)
In this series different sets of mice (each comprising 5
mice) were fed potentized drug both before and after in-
jection in similar manner as stated above and sacrificed
at the 6 different fixation intervals.
Control series (C1–C6)
Since the "vehicle" of the homeopathic drug was 90%
ethyl alcohol, the same was also potentized to form alco-
hol-30 and alcohol-200 by the homeopathic procedure
of dilutions and succussions. 1 drop (0.06 ml) each of al-
cohol-30 and alcohol-200 was then diluted separately
with 20 ml of double distilled water to produce the stock
solutions of succussed alcohol-30 and alcohol-200, re-
spectively. 1 drop (0.06 ml) each of the stock solution of
alcohol-30 and alcohol-200 was fed to separate sets of
mice (also comprising 5 mice in each set) serving as con-
trol at all corresponding intervals of the drug treated se-
ries. In earlier experiments in this laboratory another
Figure 2
Showing time-dependent frequencies of Cad Sulph-30 pre-
fed and Cad Sulph-200 pre-fed series versus their respective
CdCl2 treated alcohol-30 and alcohol-200 control mice.
Chromosome aberration (CA)-l; Mitotic index (MI)-2; Micro-
nucleated erythrocytes (MNE)-3 and Sperm head anomaly
(SHA)-4.
Figure 3
Showing time-dependent frequencies of Cad Sulph-30 pre-
fed and Cad Sulph-200 pre-fed series versus their respective
CdCl2 treated alcohol-30 and alcohol-200 control mice.
Chromosome aberration (CA)-l; Mitotic index (MI)-2; Micro-
nucleated erythrocytes (MNE)-3 and Sperm head anomaly
(SHA)-4.BMC Complementary and Alternative Medicine 2001, 1:9 http://www.biomedcentral.com/1472-6882/1/9
control with unsuccussed dilute alcohol was also used to
be maintained, but since no significant difference was
observed in the results between succussed alcohol fed se-
ries and dilute alcohol fed series, data of this control were
not considered and incorporated in the present study for
limiting the size of the tables.
One group (5 mice) of normal healthy mice were scanned
for spontaneous levels of CA, MNE, MI and SHA, and an-
other group (5 mice each), only fed with repeated doses
of Cad sulph-30 or Cad sulph-200 at intervals corre-
sponding to drug fed series, were also scanned for the
same protocols.
Laboratory methodology
Chromosome aberration (CA) study
Chromosomes were prepared from the bone marrow
cells by following the conventional colchicine-citrate-
flame-drying-Giemsa stain method. The nomenclature
of Crippa [36] was followed in grouping the chromo-
somes into five size-classes.
Mitotic Index (Ml) and Micronuclei (MNE) studies
For the study of MI and MNE, bone marrow cells of mice
not treated with colchicine were centrifuged in 1% sodi-
um citrate solution. The materials collected at the bot-
tom were then smeared on clean grease free slides and
allowed to air-dry. Air-dried slides were stained with
May-Grunwald-Giemsa as per the conventional method
[37,38].
Sperm head anomaly (SHA) study
For the study of SHA, sperm collected from epididymis
in normal saline. It was made free from fat, vas deferens
and other tissue debries. Then the material was thor-
oughly shaken to make the sperm free to suspend in the
saline solution. The sperm suspension was filtered,
spread on clean grease-free slides, air dried and stained
with Giemsa as per the routine technique [39].
Table 1: Frequency distribution of Chromosome Aberrations (CA) in 500 bone marrow cells examined (100 cells from each 
individuals).
Mitotic Index Chromosome Aberration Micronucleated Erythrocyte Sperm Head Anomaly
Fixation
Intervals
(hr)
Drug
potency
Series % ± SE % of
Increased
MI
% of
Major
CA
% of
Other
CA
% of Total
CA ± SE
% of
Prot.
% of
MN in
NCE
% of
MN in
PCE
P/N % of Total
MN in NCE
& PCE
% of
Prot.
% of SHA
± SE
% of
prot.
63 0 T 1 1.52 ± 0.20 5.4 6.2 11.6 ± 1.60 0.25 0.99 0.16 0.35 ± 0.04 1.72 ± 0.13
C1 1.34 ± 0.17 0.18 5.6 4.4 10 ± 1.45 -1.6 0.24 0.78 0.28 0.41 ± 0.04 0.06 1.62 ± 0.12 -0.1
200 1.72 ± 0.02 4.6 6 10.6 ± 1.44 0.18 1.26 0.16 0.33 ± 0.06 1.74 ± 0.09
C2 1.66 ± 0.16 0.06 4,8 5.8 10.6 ± 1.44 0 0.26 0.76 0.30 0.37 ± 0.04 0.04 1.56 ± 0.23 -0.18
12 30 T1 1.68 ± 0.11 6.8 8.4 15.2 ± 1.08 0.23 0.71 0.03 0.33 ± 0.05 1.86 ± 0.13
C1 1.38 ± 0.12 0.3 8 8.4 16.4 ± 1.75 1.2 0.4 0.6 0.47 0.47 ± 0.04 0.14a 2.04 ± 0.20 0.18
200 T2 1.88 ± 0.11 4.4 7.2 11.6 ± 1.03 0.25 0.77 0.30 0.37 ± 0.04 1.80 ± 0.15
C2 1.44 ± 0.19 0.44 6.8 8.4 15.2 ± 1.55 3.6 0.51 0.7 0.44 0.57 ± 0.06 0.20a 1.96 ± 0.25 0.16
24 30 T1 1.68 ± 0.38 9.4 13.4 22.8 ± 1.98 0.46 1.22 0.38 0.67 ± 0.06 4.40 ± 0.30
C1 1.04 ± 0.21 0.64a 15.6 13.9 29.4 ± 2.28 6.6 0.84 1.68 0.28 1.03 ± 0.07 0.36b 4.94 ± 0.29 0.54
200 T2 1.84 ± 0.37 8.2 7.6 15.8 ± 1.94 0.59 1.33 0.33 0.73 ± 0.05 4.24 ± 0.30
C2 1.11 ± 0.17 0.74 14.8 13.4 28.2 ± 1.47 12.4c 0.8 1.51 0.30 0.97 ± 0.10 0.24 4.74 ± 0.21 0.5
48 30 T1 1.86 ± 0.13 8.6 10.2 18,80,96 0.84 1.34 0.48 1.01 ± 0.08 5.24 ± 0.38
C1 1.44 ± 0.17 0.42 12.6 12.4 25 ± 1.36 6.2b 1.25 1.54 0.44 1.34 ± 0.12 0.33a 5.62 ± 0.31 0.38
200 T2 2.04 ± 0.13 8.6 7.8 16.4 ± 1.09 0.87 1.5 0.51 1.07 ± 0.07 5.08 ± 0.38
C2 1.42 ± 0.23 0.62 12.4 12 24.4 ± 0.96 8c 1.32 1.44 0.48 1.32 ± 0.11 0.25 5.68 ± 0.44 0.6
72 30 T1 2.28 ± 0.18 7.6 8.6 16.2 ± 0.89 0.7 1.23 0.45 0.89 ± 0.09 6.18 ± 0.10
C1 1.52 ± 0.10 0.76b 10 11 21 ± 1.45 4.8a 1.21 1.64 0.62 1.38 ± 0.04 0.49c 7.02 ± 0.20 0.84b
200 T2 2.5 ± 0.20 5.8 6.6 12.4 ± 1.81 0.64 1.24 0.40 0.83 ± 0.13 6.16 ± 0.24
C2 1.86 ± 0.23 0.64 9.8 9.6 19.4 ± 1.48 7b 1.5 1.16 0.59 1.38 ± 0.13 0.55a 6.98 ± 0.30 0.82
96 30 T1 1.98 ± 0.20 6 9.2 15.2 ± 0.65 0.44 1.22 0.32 0.63 ± 0.05 3.62 ± 0.54
C1 1.64 ± 0.16 0.34 9.4 9 18.4 ± 1.44 3.2 1.01 1.11 0.51 1.03 ± 0.08 0.40b 4.68 ± 0.60 1.06
200 T2 2.2 ± 0.22 5. 7 12 ± 2.44 0.39 0.95 0.33 0.53 ± 0.04 3.80 ± 0.29
C2 1.48 ± 0.10 0.72a 8.2 8.2 16.6 ± 1.15 4.6 0.91 0.96 0.53 0.93 ± 0.11 0.40b 5.12 ± 0.10 1.32b
a = p < 0.05, b = p < 0.01, c = p < 0.001 (significance levels of t-test) Mitotic Indices (MI) in 5000 cells (1000 cells from each individuals), Micronuclei 
in normochromatic erythrocytes (NCE) and polychromatic erythrocytes (PCE) in 5000 cells (1000 cells from each individuals) and Sperm head-
shape abnormality (SHA) in 5000 sperm (1000 sperm from each individuals) at different fixation intervals in CdCl2 treated mice pre-fed with Cad 
Sulph-30 (T1) and Cad Sulph-200 (T2) separately and respective alcohol-30 (C1) and alcohol-200 (C2) fed controls.BMC Complementary and Alternative Medicine 2001, 1:9 http://www.biomedcentral.com/1472-6882/1/9
Scoring of data
The observer was "blinded" during observation and scor-
ing of different parameters in the treated and control se-
ries to remove the possibility of any 'bias' during scoring
of data.
Statistical analysis
The test of significance between the data of the experi-
mental and control series was determined by Student's t-
test and the analysis of variance (two way ANOVA). The
levels of significance of t-values were determined accord-
ing to Fisher and Yates [40] statistical tables.
Results
Qualitative changes
A single injection of CdCl2 induced various types of chro-
mosome aberrations (CA) in bone marrow cells, a few
representative types of which, namely, gap (Photomicro-
graph 1a), break (Photomicrograph 1b), fragment of un-
known origin (Photomicrograph 1c), terminal
association (Photomicrograph 1d), ring and constriction
(Photomicrograph 1e), precocious centromeric separa-
tion (Photomicrograph 1f), C-mitotic effect (Photomicro-
graph 1g), pulverisation (Photomicrograph 1h), erosion
(Photomicrograph 1i) and polyploidy (Photomicrograph
1j) have been furnished. Micronucleated erythrocytes
(MNE) – both polychromatic (Photomicrograph 1k) and
normochromatic (Photomicrograph 1l) were also found
in certain bone marrow cells. Sperm with abnormal
head-shapes (Sperm head anomaly-SHA) (Photomicro-
graph 1m to 1o) were also recorded.
Quantitative changes
The frequency distributions of CA, MNE, MI and SHA in
all the drug-treated series vis-a-vis control series were
analysed. In both the normal healthy mice and mice fed
with Cad Sulph-30 and 200 in repeated doses, the fre-
quencies of CA, MNE, abnormal sperm shapes and MI
Figure 4
Showing time-dependent frequencies of Cad Sulph-30 pre-
fed and Cad Sulph-200 pre-fed series versus their respective
CdCl2 treated alcohol-30 and alcohol-200 control mice.
Chromosome aberration (CA)-l; Mitotic index (MI)-2; Micro-
nucleated erythrocytes (MNE)-3 and Sperm head anomaly
(SHA)-4.
Figure 5
Showing time-dependent frequencies of Cad Sulph-30 pre-
fed and Cad Sulph-200 pre-fed series versus their respective
CdCl2 treated alcohol-30 and alcohol-200 control mice.
Chromosome aberration (CA)-l; Mitotic index (MI)-2; Micro-
nucleated erythrocytes (MNE)-3 and Sperm head anomaly
(SHA)-4.BMC Complementary and Alternative Medicine 2001, 1:9 http://www.biomedcentral.com/1472-6882/1/9
remained more or less within the spontaneous levels.
Therefore, only the positive control (alcohol-30 or alco-
hol-200) was considered for comparison with the drug
fed series for the sake of limiting the size of the tables and
space.
Chromosome aberrations (CA) study
Drug pre-fed series
Both Cad Sulph-30 and Cad Sulph-200 could reduce the
frequencies of CA in almost all the fixation intervals ex-
cept for Cad Sulph-30 at 6 hr and the reductions were
quite significant in later intervals (p < 0.05 – p < 0.001).
The maximum protection was shown at 48 hr in case of
both the drugs after which the extent of protection de-
clined. When the efficacy of two potencies was compared
Cad Sulph-200 showed more protection in all the fixa-
tion intervals than that of Cad Sulph-30 (Table 1, Fig. 2).
Drug post-fed series
Both Cad Sulph-30 and Cad Sulph-200 could reduce the
frequencies of CA in all the fixation intervals. Both the
drugs showed maximum protection at 24 hr, after which
it declined. Again Cad Sulph-200 showed more protec-
tion in all the fixation intervals than that of Cad Sulph-30
(Table 2, Fig. 6).
Combined pre- and post-drug-fed series
Both the drugs showed significant (except for 6 hr) pro-
tections in all the fixation intervals. Cad Sulph-200
showed more protection than that of Cad Sulph-30 (Ta-
ble 3, Fig. 10).
When the modes of treatment were compared in respect
of CA it was found that post treatment was more effective
than that of pre-treatment and the combined pre and
post treatment was the most effective as compared to the
others.
Table 2: Frequency distribution of Chromosome Aberrations (CA) in 500 bone marrow cells examined (100 cells from each 
individuals).
Mitotic Index Chromosome Aberration Micronucleated Erythrocyte Sperm Head Anomaly
Intervals
(hr)
Drug
potency
Series % ± SE % of
Increased
MI
% of
Major
CA
% of
Other
CA
Total
CA ± SE
Prot. % of
MN in
NCE
% of
MN in
PCE
P/N % of
Total MN
in NCE
& PCE
% of
Prot,
% of
SHA ± SE
% of
prot.
63 0 T 3 1.72 ± 0.18 3.2 6 9.2 ± 0.82 0.15 1.07 0.12 0.25 ± 0.04 1.62 ± 0.20
C3 1.84 ± 0.20 -0.12 3.8 7.4 11.2 ± 0.96 2.0 0.23 0.73 0.32 0.35 ± 0.02 0.10a 1.68 ± 0.25 0.06
200 T4 1.98 ± 0.23 3.4 5.2 8.6 ± 1.20 0.2 0.67 0.13 0.25 ± 0.04 1.48 ± 0.19
C4 1.6 ± 0.18 0.38 5 6.6 11.6 ± 1.44 3.0 0.23 0.51 0.30 0.29 ± 0.03 0.04a 1.56 ± 0.18 0.08
12 30 T3 1.84 ± 0.14 6 6.8 12.8 ± 0.82 0.2 0.58 0.25 0.27 ± 0.04 1.64 ± 0.18
C3 1,36 ± 0,17 0.48 7.6 9.8 17.4 ± 1.44 4.6a 0.43 0.64 0.45 0.49 ± 0.05 0.22a 2.12 ± 0.26 0.48
200 T4 2.08 ± 0.14 4.8 4.8 9.6 ± 1.03 0.17 0.41 0.23 0.21 ± 0.02 1.32 ± 0.16
C4 1.38 ± 0.19 0.7a 6.8 9.8 16.6 ± 1.60 7.0a 0.4 0.57 0.45 0.47 ± 0.06 0.26a 2.04 ± 0.23 0.72a
24 30 t3 1.7 ± 0.33 8.2 9.4 17.6 ± 1.52 0.54 1 0.31 0.65 ± 0.05 3.6 ± 0.24
C3 1.1 ± 0.21 0.6 15.2 14.6 29.8 ± 1.55 12.2c 0.81 1.44 0.28 0.95 ± 0.08 0.30a 4.98 ± 0.28 1.38b
200 T4 1.88 ± 0.35 6.6 6.6 13.2 ± 2.07 0.36 0.62 0.40 0.43 ± 0.04 3.1 ± 0.24
C4 0.98 ± 0.22 0.9 16.4 14.2 30.6 ± 1.56 17.4c 0.86 1.69 0.28 1.05 ± 0.07 0.62c 5.12 ± 0.28 2.02c
48 30 t3 2 ± 0.16 7.8 9 16.8 ± 0.77 0.54 0.76 0.45 0.61 ± 0.08 4.56 ± 0.39
C3 0.98 ± 0.14 1.02b 11 12.8 23.8 ± 1.34 7.0b 1.34 1.28 0.54 1.32 ± 0.08 0.71c 5.9 ± 0.41 1.34a
200 T4 2.34 ± 0.16 7 7.4 14.4 ± 0.90 0.32 0.41 0.50 0.35 ± 0.02 4.06 ± 0.39
C4 1.06 ± 0.13 1.28c 12 13.8 25.8 ± 0.96 11.4c 1.15 1.41 0.50 1.22 ± 0.04 0.87c 6.02 ± 0.38 1.96b
72 30 t3 2.76 ± 0.21 5.6 7.2 12.8 ± 1.38 0.47 0.64 0.33 0.51 ± 0.06 7.64 ± 0.16
C3 1.7 ± 0.18 1.06b 9.6 10.4 20 ± 1.45 7.2b 1.65 1.06 0.58 1.44 ± 0.09 0.93c 7.74 ± 0.30 0.10
200 T4 2.9 ± 0.22 6.6 4.4 11 ± 1.50 0.26 0.59 0.30 0.33 ± 0.05 4.86 ± 0.33
C4 1.56 ± 0.07 1.34c 9.4 11.2 20.6 ± 1.64 9.6c 1.17 1.62 0.60 1.32 ± 0.08 0.99c 7.28 ± 0.20 2.42c
96 30 t3 2.3 ± 0.23 4.6 7.6 12.2 ± 1.14 0.28 0.92 0.17 0.37 ± 0.06 2.72 ± 0.18
C3 1.26 ± 0.15 1.04c 8.2 10.2 18.4 ± 1.60 6.2a 0.86 0.94 0.49 0.91 ± 0.09 0.54c 4.64 ± 0.34 1.92b
200 T4 2.56 ± 0.26 3.2 5.6 9.8 ± 1.24 0.18 0.71 0.16 0.25 ± 0.02 2.38 ± 0.24
C4 1.42 ± 0.10 1.14b 7.4 10.4 17.6 ± 1.60 7.8b 0.94 1.01 0.49 0.97 ± 0.09 0.72c 5.14 ± 0.19 2.76c
a = p < 0.05, b = p < 0.01, c = p < 0.001 (significance levels of t-test) Mitotic Indices (MI) in 5000 cells (1000 cells from each individuals), Micronuclei 
in normochromatic erythrocytes (NCE) and polychromatic erythrocytes (PCE) in 5000 cells (1000 cells from each individuals) and Sperm head-
shape abnormality (SHA) in 5000 sperm (1000 sperm from each individuals) at different fixation intervals in CdCl2 treated mice post-fed with Cad 
Sulph-30 (T3) and Cad Sulph-200 (T4) separately and respective alcohol-30 (C3) and alcohol-200 (C4) fed controls.BMC Complementary and Alternative Medicine 2001, 1:9 http://www.biomedcentral.com/1472-6882/1/9
Mitotic Index (Ml) study
Drug pre-fed series
Both Cad Sulph-30 and Cad Sulph-200 could enhance
the frequencies of MI in all the fixation intervals and the
maximum enhancement was shown at the later intervals
(24–96 hr). When the efficacy of two drugs were com-
pared Cad Sulph-200 showed more enhancement of MI
than that of Cad Sulph-30 in almost all the fixation inter-
vals except for 72 hr where it was just the opposite (Table
1, Fig. 3).
Drug post-fed series
Both the drugs could enhance the frequencies of MI in all
the fixation intervals and the maximum enhancement
was shown at 72 hr (p < 0.01 in case of Cad sulph-30 and
p < 0.001 in case of Cad sulph-200). Again when the ef-
ficacy of two drugs were compared Cad Sulph-200
showed more enhancement of MI than that of Cad
Sulph-30 in all the fixation intervals (Table 2, Fig. 7).
Combined pre and post drug-fed series
Both the drugs showed increase in MI at all the fixation
intervals and those were statistically significant except
for 6 hr. Further, Cad Sulph-200 increased MI more than
that of Cad Sulph-30 (Table 3, Fig. 11).
When the modes of treatment were compared in respect
of MI, it was found that post treatment was more effec-
tive than that of pre-treatment and the combined pre-
and post-treatment was the most effective.
Micronuclei (MN) study
Drug pre-fed series
Both Cad Sulph-30 and Cad Sulph-200 could reduce the
frequencies of NCE, PCE and total MNE in all the fixa-
tion intervals. The maximum protection was shown at 24
hr in case of both the drugs and after that it declined.
When the efficacy of two drugs was compared Cad Sulph-
200 showed more protection in all the fixation intervals
than that of Cad Sulph-30 (Table 1, Fig. 4).
Table 3: Frequency distribution of Chromosome Aberrations (CA) in 500 bone marrow cells examined (100 cells from each 
individuals).
Mitotic Index Chromosome Aberration Micronucleated Erythrocyte Sperm Head Anomaly
Intervals 
(hr)
Drug 
potency
% ± SE % of
Increased
MI.
% of
Major
CA
% of
Other
CA
% of Total
CA ± SE
% of
Prot.
% of
MN in
NCE
% of
MN in
PCE
P/N % of
Total MN
in NCE
& PCE
% of
Prot.
% of
SHA ± SE
% of
prot.
63 0 T 5 1.84 ± 0.22 3.4 5.4 8.8 ± 1.14 0.15 0.58 0.11 0.21 ± 0.02 1.6 ± 0.15
C5 1.42 ± 0.14 0.42 4.4 6 10.4 ± 1.82 1.6 0.31 0.72 0.33 0.41 ± 0.04 0.20a 1.64 ± 0.07 0.04
200 T6 2.1 ± 0.25 2 3 5 ± 1.17 0.14 0.7 0.24 0.22 ± 0.05 1.72 ± 0.17
C6 1.48 ± 0.16 0.62 4.2 4.6 10.8 ± 1.14 5.8 0.33 1.06 0.51 0.48 ± 0.05 0.26b 1.5 ± 0.12 -0.22
12 30 T5 2.24 ± 0.12 4.8 6.4 11.2 ± 0.65 0.16 0.59 0.20 0.27 ± 0.02 1.7 ± 0.22
C5 1.56 ± 0.13 0.68b 8 9.4 17.4 ± 1.68 6.2b 0.43 0.77 0.49 0.55 ± 0.05 0.32c 2.16 ± 0.28 0.46a
200 T6 2.42 ± 0.12 3 4.8 7.4 ± 0.74 0.14 0.38 0.18 0.17 ± 0.02 1.52 ± 0.19
C6 1.46 ± 0.13 0.96c 5.8 10.2 16 ± 1.54 8.2c 0.36 0.81 0.45 0.51 ± 0.04 0.34c 2.12 ± 0.21 0.6
24 30 T5 2.04 ± 0.18 6.0 6.6 12.6 ± 1.2 0.31 1 0.31 0.47 ± 0.04 3.02 ± 0.19
C5 1.1 ± 0.20 0.94b 14.6 15.6 30.2 ± 1.63 17.6c 0.91 1.81 0.32 1.12 ± 0.08 0.77c 5.09 ± 0.30 2.07c
200 T6 2.28 ± 0.26 4.8 5.6 10.4 ± 1.30 0.18 0.47 0.32 0.25 ± 0.02 2.64 ± 0.23
C6 0.98 ± 0.17 1.3b 13.4 18.4 31.8 ± 1.55 21.4c 0.87 1.72 0.30 1.05 ± 0.10 0.80c 4.96 ± 0.57 2.32b
48 30 T5 2.44 ± 0.09 5.6 5.8 11.4 ± 1.03 0.36 0.53 0.51 0.41 ± 0.06 3.64 ± 0.29
C5 1.44 ± 0.20 1b 12.4 13.6 26 ± 1.87 14.6c 0.98 1.63 0.46 1.20 ± 0.04 0.79 5.64 ± 0.34 2b
200 T6 2.84 ± 0.16 5.0 5.8 10.8 ± 1.14 0.12 0.44 0.55 0.23 ± 0.02 3.38 ± 0.35
C6 1.16 ± 0.13 1.68c 13.0 14 27 ± 1.11 16.2c 1.06 1.56 0.49 1.22 ± 0.05 0.99c 5.74 ± 0.32 2.36b
72 30 T5 2.86 ± 0.14 3.2 5.6 8.8 ± 1.14 0.7 1.23 0.46 0.89 ± 0.09 4.72 ± 0.23
C5 1.68 ± 0.09 1.18c 8.0 9.4 17.4 ± 1.51 8.6c 1.21 1.64 0.57 1.38 ± 0.04 0.49c 7.06 ± 0.24 2.34c
200 T6 3.18 ± 0.28 3.6 4.8 8.4 ± 1.33 0.12 0.55 0.27 0.21 ± 0.04 5.38 ± 0.20
C6 1.6 ± 0.09 1.58c 9.0 12.4 21.4 ± 1.30 13c 1.45 0.64 0.64 1.38 ± 0.09 1.17c 7.96 ± 0.35 2.58c
96 30 T5 2.68 ± 0.24 3.8 4.8 8.6 ± 0.90 0.27 0.69 0.29 0.37 ± 0.02 2.18 ± 0.15
C5 1.68 ± 0.13 1.00b 9.2 10 19.2 ± 1.55 10.6c 1.18 1.34 0.46 1.20 ± 0.04 0.83c 4.88 ± 0.30 2.7c
200 T6 3 ± 0.23 3.6 4.4 8 ± 0.61 0.15 0.29 0.29 0.23 ± 0.02 1.86 ± 0.13
C6 1.58 ± 0.13 1.42b 9.0 9.8 18.8 ± 1.31 10.8c 1.06 0.45 0.45 1.10 ± 0.07 0.87c 5.02 ± 0.14 3.16c
a = p < 0.05, b = p < 0.01, c = p < 0.001 (significance levels of t-test) Mitotic Indices (MI) in 5000 cells (1000 cells from each individuals), Micronuclei 
in normochromatic erythrocytes (NCE) and polychromatic erythrocytes (PCE) in 5000 cells (1000 cells from each individuals) and Sperm head-
shape abnormality (SHA) in 5000 sperm (1000 sperm from each individuals) at different fixation intervals in CdCl2 treated mice combined pre- and 
post-fed with Cad Sulph-30 (T5) and Cad Sulph-200 (T6) separately and respective alcohol-30 (C5) and alcohol-200 (C6) fed controls.BMC Complementary and Alternative Medicine 2001, 1:9 http://www.biomedcentral.com/1472-6882/1/9
Drug post-fed series
Both the drugs could reduce the frequencies of NCE, PCE
and total MNE in all the fixation intervals and the differ-
ences were statistically significant in almost all the fixa-
tion intervals (except for Cad Sulph-200 at 6 hr). Cad
Sulph-200 showed more protective ability than that of
Cad Sulph-30 (Table 2, Fig. 8).
Combined pre and post drug-fed series
Both the potencies showed remarkable efficiency in re-
ducing the frequencies of NCE, PCE and total MNE in all
the fixation intervals and the differences were statistical-
ly highly significant (p < 0.001). Cad Sulph-200 showed
more protection than Cad Sulph-30 (Table 3, Fig. 12).
When the modes of treatment were compared it was no-
ticed that both the drugs could show more protection in
combined pre- and post-feeding followed by only post-
feeding.
Sperm head anomaly (SHA) study
Drug pre-fed series
Both Cad Sulph-30 and 200 could reduce the frequen-
cies of sperm with abnormal head shapes in almost all
the fixation intervals except for 6 hr and the 200th poten-
cy showed more protection than that of the 30th potency
(Table 1, Fig. 5).
Drug post-fed series
Both the potencies showed reductions in frequencies of
sperm with abnormal head shapes in all the fixation in-
tervals and the differences were statistically significant
in almost all the fixation intervals except for 6 hr. Cad
Sulph-200 showed more protective ability than that of
Cad Sulph-30 (Table 2, Fig. 6).
Combined pre and post drug-fed series
The same trend was noticed for both potencies of the
drug (except for Cad Sulph-200 at 6 hr) (Table 3, Fig. 13).
Figure 6
Showing time-dependent frequencies of Cad Sulph-30 post-
fed and Cad Sulph-200 post-fed series versus their respective
CdCl2 treated alcohol-30 and alcohol-200 control mice.
Chromosome aberration (CA)-5; Mitotic index (MI)-6;
Micronucleated erythrocytes (MNE)-7 and Sperm head
anomaly (SHA)-8.
Figure 7
Showing time-dependent frequencies of Cad Sulph-30 post-
fed and Cad Sulph-200 post-fed series versus their respective
CdCl2 treated alcohol-30 and alcohol-200 control mice.
Chromosome aberration (CA)-5; Mitotic index (MI)-6;
Micronucleated erythrocytes (MNE)-7 and Sperm head
anomaly (SHA)-8.BMC Complementary and Alternative Medicine 2001, 1:9 http://www.biomedcentral.com/1472-6882/1/9
The maximum protective ability of both potencies of the
drug was noticed in combined pre- and post-feeding fol-
lowed by post-and pre-feeding.
Discussion
From the results of the present investigation it is re-
vealed that both Cad Sulph-30 and Cad Sulph-200
showed remarkable potential to reduce genotoxic effects
produced by CdCl2 although the drug itself had no palpa-
ble genotoxic effects of its own when fed to normal
healthy mice. Incidentally the results were essentially
similar to different potencies of Ars Alb used against ar-
senic poisoning [30–35,41,42]. It would also be revealed
clearly that Cad sulph-200 rendered more pronounced
protective effect, particularly at longer fixation intervals.
Cadmium poisoning in certain areas, particularly at or
near Zinc mines and Zinc processing factories, paint in-
dustries, has crossed tolerable limits. Incidentally, cad-
mium has been reported to significantly inhibit E. coli
and human DNA polymerase activity [43,44]. When
growing cultures of E. coli were exposed to cadmium,
considerable single-strand breaks were reported to occur
in DNA [45]. Further, Privezentsev et al[46] reported
that cadmium genotoxicity observed in both in vivo and
in vitro cells of mice would be due to single-strand
breaks in DNA through the direct cadmium-DNA inter-
actions. In our present study also, we noted quite a good
number of plates with clear chromosomal damage indic-
ative of DNA breaks and other forms of lesions. There-
fore, the search for a protective agent which may be used
without any fear or risk of toxic side effects to prevent/
repair such damages seemed to us to be important. From
the encouraging and positive modulating action of the
potentized Cad Sulph observed in the present study,
these drugs could be suggested as strong candidates for
combating unintentional/accidental exposure to sub-
Figure 8
Showing time-dependent frequencies of Cad Sulph-30 post-
fed and Cad Sulph-200 post-fed series versus their respective
CdCl2 treated alcohol-30 and alcohol-200 control mice.
Chromosome aberration (CA)-5; Mitotic index (MI)-6;
Micronucleated erythrocytes (MNE)-7 and Sperm head
anomaly (SHA)-8.
Figure 9
Showing time-dependent frequencies of Cad Sulph-30 post-
fed and Cad Sulph-200 post-fed series versus their respective
CdCl2 treated alcohol-30 and alcohol-200 control mice.
Chromosome aberration (CA)-5; Mitotic index (MI)-6;
Micronucleated erythrocytes (MNE)-7 and Sperm head
anomaly (SHA)-8.BMC Complementary and Alternative Medicine 2001, 1:9 http://www.biomedcentral.com/1472-6882/1/9
acute cadmium poisoning, both as a preventive as well as
curative agent.
In the present study the homeopathic drug apparently
enhanced/activated the process of maintaining the
structural integrity of chromosomes and sperm either
protecting them from the destructive ability of CdCl2 in
causing DNA damage or else, by enhancing the process
of repair of DNA already damaged by activating specific
enzyme systems to repair the damage.
Incidentally, there are inherent mechanisms of DNA and
chromosome repairs [47,48] which are known to be ge-
netically controlled. The same is true for the regulation of
cell cycle events. In the present study also we have noted
a positive shift in the mitotic index in the CdCl2-fed mice
which may be linked to the replenishment of bone mar-
row cells, the necessity arising out of the exclusion/loss
of damaged marrow cells due to the toxic chemical inter-
action of CdCl2 to chromosome components primarily
made up of DNA and protein. The repair mechanisms of
chromosomes, therefore, also involved inherent mecha-
nisms for repair of protein damage, a process also under
a precise genetical control [47–49]. Therefore, any
mechanism that can repair/protect cytogenetical effects
must necessarily be regulated by specific genetic mecha-
nisms essentially controlled by specific genes. Theoreti-
cally speaking even in the absence of a single original
drug molecule both Cad Sulph-30 and 200 elicited spec-
tacular ability of protection/repair to damaged chromo-
somes and sperm, a fact which would lead one to
speculate that the drugs must have acted through the ge-
netic regulatory mechanisms. In fact, Khuda-Bukhsh
[50] explained the possible mechanism of action of the
potentized homeopathic drugs by suggesting that one
major way by which the potentized homeopathic drugs
acted was possibly through regulation of expression of
certain genes. This could be achieved by activating cer-
Figure 10
Showing time-dependent frequencies of Cad Sulph-30 com-
bined pre- and post-fed and Cad Sulph-200 combined pre-
and post-fed series versus their respective CdCl2 treated
alcohol-30 and alcohol-200 control mice. Chromosome
aberration (CA)-9; Mitotic index (MI)-10; Micronucleated
erythrocytes (MNE)-11 and Sperm head anomaly (SHA)-12.
Figure 11
Showing time-dependent frequencies of Cad Sulph-30 com-
bined pre- and post-fed and Cad Sulph-200 combined pre-
and post-fed series versus their respective CdCl2 treated
alcohol-30 and alcohol-200 control mice. Chromosome
aberration (CA)-9; Mitotic index (MI)-10; Micronucleated
erythrocytes (MNE)-11 and Sperm head anomaly (SHA)-12.BMC Complementary and Alternative Medicine 2001, 1:9 http://www.biomedcentral.com/1472-6882/1/9
tain hormones and enzymes through transduction of
specific regulatory signals including transcription fac-
tors (either inducive or repressive in nature) on target
cells, in order to get them back to their normal state of
functioning. The results of this study will also strengthen
this view.
Conclusion
In conclusion, it may be pointed out that the two micro-
doses of Cad Sulph were capable of rendering protec-
tion/repair to the genotoxic damages caused by the
treatment of the toxic chemical, CdCl2, and these were
most effective when the combined pre- and post-feeding
mode was followed. However, only post-feeding also
proved to be effective in restoring the damages to a con-
siderable extent. Interesting to note, however, is the fact
that the more diluted, or the 200th potency appeared to
have more pronounced efficacy in rendering protective
effects than that of the 30th potency, as is claimed in the
homeopathic literature. Since there is also some amount
of protective effects of Cad Sulph against CdCl2 poison-
ing, and since combined pre- and post-feeding mode ap-
peared to show the maximum protective effect, and since
Cad Suplh itself had no damaging effects of its own on
the genome, the preventive administration of Cad Suplh
to people living in contaminated zone may be consid-
ered.
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